{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:46Z","timestamp":1790983126221,"version":"4.1.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Onconephrology is an emerging subspecialty that encompasses comprehensive kidney management in patients with cancer. Trastuzumab emtansine (T-DM1) is an antibody\u2013drug conjugate composed of trastuzumab linked to the microtubule inhibitor. T-DM1 is widely used in the treatment of human epidermal growth factor receptor 2-positive breast cancer, and glomerular disease arising during T-DM1 therapy remains rarely reported. The present report describes the case of a 50-year-old Japanese woman who developed nephrotic-range proteinuria approximately five months after initiating T-DM1 adjuvant therapy. Kidney biopsy confirmed the diagnosis of cellular variant focal segmental glomerulosclerosis. Other secondary causes, including autoimmune disease and infection, were excluded, and the temporal relationship between symptom onset and T-DM1 administration suggested a possible drug-related etiology. Given the absence of alternative treatment regimens for her breast cancer, we decided to continue T-DM1 without immunosuppressive therapy, with careful monitoring of kidney function and proteinuria. The scheduled anticancer treatment course was successfully completed, and proteinuria improved significantly within 7 weeks of treatment completion. This case highlights the importance of recognizing rare glomerular adverse effects of T-DM1 and underscores the need to carefully balance oncological treatment benefits against renal toxicity, emphasizing the value of multidisciplinary collaboration between oncologists and nephrologists.<\/jats:p>","DOI":"10.3389\/fonc.2026.1871262","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:24:55Z","timestamp":1785745495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cellular variant focal segmental glomerulosclerosis during trastuzumab emtansine treatment in HER2-positive breast cancer: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Soshi","family":"Okada","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae","family":"Aratani","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School","place":["Tokyo, Japan"]},{"name":"Division of Cancer Cell Biology, Institute of Medical Science, University of Tokyo","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School","place":["Tokyo, Japan"]},{"name":"Department of Nephrology, Nippon Medical School Musashikosugi Hospital","place":["Kawasaki-shi, Kanagawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masujiro","family":"Makita","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Nippon Medical School Musashikosugi Hospital","place":["Kawasaki-shi, Kanagawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Murasato","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Nippon Medical School Musashikosugi Hospital","place":["Kawasaki-shi, Kanagawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideko","family":"Hoshina","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Nippon Medical School Musashikosugi Hospital","place":["Kawasaki-shi, Kanagawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Hirama","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Shintani-Domoto","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Nippon Medical School","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kashiwagi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Nippon Medical School","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Iwabu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000495","article-title":"Onconephrology fellowship training: Current status and future outlook","volume":"5","author":"Bonilla","year":"2024","journal-title":"Kidney360"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2025.2590283","article-title":"Anticancer drug-induced nephrotoxicity: Biopsy-proven patterns and outcomes across chemotherapy, targeted therapy, and immune checkpoint inhibitors","volume":"47","author":"Tian","year":"2025","journal-title":"Ren Fail"},{"key":"B3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13730-021-00636-4","article-title":"Clinicopathological characteristics of kidney injury in non-small cell lung cancer patients under combination therapy including pembrolizumab","volume":"11","author":"Aratani","year":"2022","journal-title":"CEN Case Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.JNMS.2022_89-221","article-title":"Current trends in anti-cancer molecular targeted therapies: Renal complications and their histological features","volume":"89","author":"Tonooka","year":"2022","journal-title":"J Nippon Med Sch"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab emtansine (T-DM1): An antibody-drug conjugate (ADC) for HER2-positive breast cancer","volume":"57","author":"Lambert","year":"2014","journal-title":"J Med Chem"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): A descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000480492","article-title":"Adverse events of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive breast cancer patients","volume":"12","author":"Kowalczyk","year":"2017","journal-title":"Breast Care (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.10.024","article-title":"Pathologic classification of focal segmental glomerulosclerosis: A working proposal","volume":"43","author":"D\u2019Agati","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating primary, genetic, and secondary FSGS in adults: A clinicopathologic approach","volume":"29","author":"De Vriese","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv072","article-title":"Distinguishing age-related from disease-related glomerulosclerosis on kidney biopsy: The aging kidney anatomy study","volume":"30","author":"Kremers","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"D\u2019Agati","year":"2011","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nrneph.2014.216","article-title":"Causes and pathogenesis of focal segmental glomerulosclerosis","volume":"11","author":"Fogo","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05960616","article-title":"Focal segmental glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic inhibition of VEGF signaling and associated nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41572-025-00671-w","article-title":"Podocytopathies","volume":"11","author":"Romagnani","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis-treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw338","article-title":"Nephrotoxicity of anticancer treatment","volume":"32","author":"Malyszko","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/ckj\/sft135","article-title":"Nephrotoxicity of recent anti-cancer agents","volume":"7","author":"Lameire","year":"2014","journal-title":"Clin Kidney J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-015-0226-9","article-title":"Renal toxicity of anticancer agents targeting HER2 and EGFR","volume":"28","author":"Cosmai","year":"2015","journal-title":"J Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.796223","article-title":"Case report: Collapsing focal segmental glomerulosclerosis after initiation of ado-trastuzumab emtansine therapy","volume":"11","author":"Hakroush","year":"2021","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03770412","article-title":"Onco-nephrology: Glomerular diseases with cancer","volume":"7","author":"Cambier","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26461","article-title":"Payload of T-DM1 binds to cell surface cytoskeleton-associated protein 5 to mediate cytotoxicity of hepatocytes","volume":"9","author":"Endo","year":"2018","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.04.012","article-title":"Upregulation of HER2 in tubular epithelial cell drives fibroblast activation and renal fibrosis","volume":"96","author":"Li","year":"2019","journal-title":"Kidney Int"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1871262\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:24:56Z","timestamp":1785745496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1871262\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":25,"alternative-id":["10.3389\/fonc.2026.1871262"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1871262","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"article-number":"1871262"}}